European Patent to Strengthen Medigene's Dendritic Cell (DC) Vaccines Program

06-Mar-2015 - Germany

Medigene AG  announces that the European Patent Office has granted European Patent No. 2004807 "Composition for the preparation of mature dendritic cells", relating to the manufacturing of mature dendritic cells co-developed by scientists of today's Medigene Immunotherapies. The patent will have a term until 2027 and is licensed exclusively to Medigene Immunotherapies (formerly Trianta Immunotherapies) by the Helmholtz Zentrum München.

Prof. Dolores Schendel, CSO of Medigene AG, comments: "This new patent will substantially extend the protection for our innovative products. The patent protects our unique process to generate polarised dendritic cells, the cocktail used in the process and the derived polarised dendritic cells, which are being used in the ongoing academic clinical trials and will be used in our upcoming company-sponsored clinical study."

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...